Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$22.80 USD
+2.30 (11.22%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.80 0.00 (0.00%) 4:30 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.80 USD
+2.30 (11.22%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.80 0.00 (0.00%) 4:30 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
Zacks News
BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial
by Zacks Equity Research
BrainsWay (BWAY) emphasizes the potential of the accelerated protocol, citing previous data suggesting comparable outcomes with traditional, longer protocols.
Zimmer Biomet (ZBH) Advances in GenAI Technology With RevelAi
by Zacks Equity Research
Zimmer Biomet (ZBH) and RevelAi Health have joined forces to solve social and clinician problems by commercializing RevelAi's patient care-management platform and care team dashboard for providers.
Thermo Fisher's (TMO) New Launch Supports Full Lab Automation
by Zacks Equity Research
Thermo Fisher's (TMO) first-of-its-kind innovation for CO2 incubators supports emerging automated cell therapy production processes.
Zimmer Biomet (ZBH) to Broaden Knee Surgery Line With New Alliance
by Zacks Equity Research
Zimmer Biomet (ZBH) joins forces with Think Surgical for the distribution of customized TMINI - Miniature Robotic System in the U.S. market.
Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation
by Zacks Equity Research
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
Neogen's (NEOG) MDS Secures New Contract From USDA FSIS
by Zacks Equity Research
Neogen's (NEOG) MDS gets recognized by the USDA FSIS as the primary method for the detection of Salmonella and Listeria monocytogenes testing for meat, poultry and egg products.
Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?
by Zacks Equity Research
The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.
Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch
by Zacks Equity Research
One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.
Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark
by Zacks Equity Research
Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.
Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems
by Zacks Equity Research
Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.
Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $22.04, moving +1.94% from the previous trading session.
Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes
by Zacks Equity Research
Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.
Charles River (CRL) Partners to Reduce Animal Research Usage
by Zacks Equity Research
Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.
Align Technology (ALGN) Gains From New Alliances, Global Growth
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
by Zacks Equity Research
Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.
QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform
by Zacks Equity Research
QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.
Here's Why Omnicell (OMCL) Should be in Your Portfolio Now
by Zacks Equity Research
A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).
Medtronic (MDT) Cardiovascular Business Expands Amid Macro Woes
by Zacks Equity Research
For Hugo surgical robot, Medtronic (MDT) is scaling manufacturing production, expanding regulatory approvals and ramping up installations to see continued progress internationally.
ICON (ICRL) Gains From Strategic Acquisitions, Innovation
by Zacks Equity Research
In addition to its focused efforts within the biotech segment, ICON (ICLR) continues to drive forward its leadership in large pharma.
Here's Why Thermo Fisher (TMO) Should be in Your Portfolio
by Zacks Equity Research
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Henry Schein (HSIC) Banks on Global Expansion Amid Macro Issues
by Zacks Equity Research
Within the Dental business, Henry Schein (HSIC) is aiming to deliver customized solutions, leveraging market insights and technological advancements.
IDEXX (IDXX) Expands Test Menu for the Catalyst Platform
by Zacks Equity Research
IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.
5 Phenomenal Relative Price Strength Stocks to Snap Up Now
by Nilanjan Choudhury
VITL, HIMS, ANF, CHWY and GPS are five stocks with explosive relative price strength.
Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.